Ensign Peak Advisors
NMRA icon

Ensign Peak Advisors’s Neumora Therapeutics NMRA Stock Holding History

Ensign Peak Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150,000
Closed -$1.59M – 1710
2024
Q4 		$1.59M Hold
150,000
– – ﹤0.01% 1055
2024
Q3 		$1.98M Hold
150,000
– – ﹤0.01% 960
2024
Q2 		$1.47M Hold
150,000
– – ﹤0.01% 1044
2024
Q1 		$2.06M Hold
150,000
– – ﹤0.01% 913
2023
Q4 		$2.56M Hold
150,000
– – 0.01% 816
2023
Q3 		$2.12M Buy
+150,000
New +$1.87M ﹤0.01% 821

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Ensign Peak Advisors's NMRA Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 150,000 shares — an estimated $1.59M sold.

Ensign Peak Advisors first reported a position in NMRA in Q3 2023 and held it in 6 quarters. The position peaked at $2.56M in Q4 2023. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Ensign Peak Advisors reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 150,000 Neumora Therapeutics shares in Q1 2025, an estimated $1.59M.
  • Ensign Peak Advisors first reported a position in Neumora Therapeutics in Q3 2023 and held it in 6 quarters.
  • Ensign Peak Advisors's Neumora Therapeutics position peaked at $2.56M in Q4 2023.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.